Trade Vir Biotechnology, Inc. - VIR CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.09 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Vir Biotechnology Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 9.14 |
Open* | 9.04 |
1-Year Change* | -54.57% |
Day's Range* | 8.78 - 9.04 |
52 wk Range | 11.48-31.55 |
Average Volume (10 days) | 1.07M |
Average Volume (3 months) | 26.51M |
Market Cap | 1.55B |
P/E Ratio | -100.00K |
Shares Outstanding | 134.25M |
Revenue | 490.72M |
EPS | -1.97 |
Dividend (Yield %) | N/A |
Beta | 0.17 |
Next Earnings Date | Nov 1, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 3, 2023 | 9.14 | 0.17 | 1.90% | 8.97 | 9.15 | 8.87 |
Oct 2, 2023 | 8.95 | -0.32 | -3.45% | 9.27 | 9.29 | 8.90 |
Sep 29, 2023 | 9.32 | 0.07 | 0.76% | 9.25 | 9.45 | 9.23 |
Sep 28, 2023 | 9.16 | 0.02 | 0.22% | 9.14 | 9.25 | 9.05 |
Sep 27, 2023 | 9.21 | -0.01 | -0.11% | 9.22 | 9.35 | 9.05 |
Sep 26, 2023 | 9.20 | 0.12 | 1.32% | 9.08 | 9.54 | 9.08 |
Sep 25, 2023 | 9.15 | -0.12 | -1.29% | 9.27 | 9.30 | 8.97 |
Sep 22, 2023 | 9.30 | 0.23 | 2.54% | 9.07 | 9.47 | 8.85 |
Sep 21, 2023 | 9.07 | -0.15 | -1.63% | 9.22 | 9.28 | 9.03 |
Sep 20, 2023 | 9.32 | -0.44 | -4.51% | 9.76 | 9.85 | 9.31 |
Sep 19, 2023 | 9.80 | 0.31 | 3.27% | 9.49 | 9.80 | 9.49 |
Sep 18, 2023 | 9.59 | -0.01 | -0.10% | 9.60 | 9.73 | 9.43 |
Sep 15, 2023 | 9.75 | -0.23 | -2.30% | 9.98 | 10.10 | 9.69 |
Sep 14, 2023 | 9.99 | 0.02 | 0.20% | 9.97 | 10.22 | 9.85 |
Sep 13, 2023 | 9.95 | -0.52 | -4.97% | 10.47 | 10.56 | 9.94 |
Sep 12, 2023 | 10.45 | -0.05 | -0.48% | 10.50 | 10.77 | 10.43 |
Sep 11, 2023 | 10.67 | -0.31 | -2.82% | 10.98 | 11.19 | 10.41 |
Sep 8, 2023 | 10.94 | -0.17 | -1.53% | 11.11 | 11.11 | 10.50 |
Sep 7, 2023 | 11.50 | -0.43 | -3.60% | 11.93 | 11.95 | 11.44 |
Sep 6, 2023 | 12.04 | -0.18 | -1.47% | 12.22 | 12.23 | 11.81 |
Vir Biotechnology, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 1, 2023 | ||
Time (UTC) 10:59 | Country US
| Event Q3 2023 Vir Biotechnology Inc Earnings Release Q3 2023 Vir Biotechnology Inc Earnings ReleaseForecast -Previous - |
Wednesday, February 21, 2024 | ||
Time (UTC) 21:00 | Country US
| Event Q4 2023 Vir Biotechnology Inc Earnings Release Q4 2023 Vir Biotechnology Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1615.8 | 1095.42 | 76.368 | 8.091 | 10.668 |
Revenue | 1615.8 | 1095.42 | 76.368 | 8.091 | 10.668 |
Total Operating Expense | 782.729 | 674.664 | 373.348 | 186.07 | 129.36 |
Selling/General/Admin. Expenses, Total | 161.762 | 160.793 | 70.937 | 37.598 | 29.131 |
Research & Development | 474.148 | 447.506 | 301.411 | 147.272 | 99.129 |
Depreciation / Amortization | 0.5 | 0.5 | 1 | 1.2 | 1.1 |
Unusual Expense (Income) | |||||
Operating Income | 833.068 | 420.751 | -296.98 | -177.979 | -118.692 |
Interest Income (Expense), Net Non-Operating | -83.048 | 138.488 | 2.836 | 8.511 | 2.54 |
Other, Net | 4.26 | -9.437 | -4.467 | -5.061 | -0.212 |
Net Income Before Taxes | 754.28 | 549.802 | -298.611 | -174.529 | -116.364 |
Net Income After Taxes | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Net Income Before Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Net Income | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Income Available to Common Excl. Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Income Available to Common Incl. Extra. Items | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Diluted Net Income | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Diluted Weighted Average Shares | 134.811 | 133.437 | 119.159 | 30.3499 | 109.397 |
Diluted EPS Excluding Extraordinary Items | 3.82637 | 3.9613 | -2.50643 | -5.75563 | -1.0593 |
Diluted Normalized EPS | 3.82637 | 3.9613 | -2.50643 | -5.75563 | -1.0593 |
Total Extraordinary Items | 0 | ||||
Cost of Revenue, Total | 146.319 | 65.865 | |||
Gross Profit | 1469.48 | 1029.55 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 3.797 | 62.957 | 49.41 | 374.557 | -40.629 |
Revenue | 3.797 | 62.957 | 49.41 | 374.557 | -40.629 |
Cost of Revenue, Total | 0.022 | 1.907 | 5.996 | 22.253 | 27.921 |
Gross Profit | 3.775 | 61.05 | 43.414 | 352.304 | -68.55 |
Total Operating Expense | 218.983 | 206.328 | 199.912 | 179.593 | 184.593 |
Selling/General/Admin. Expenses, Total | 47.101 | 46.778 | 38.743 | 43.174 | 41.59 |
Research & Development | 171.86 | 157.643 | 155.173 | 114.166 | 115.082 |
Operating Income | -215.186 | -143.371 | -150.502 | 194.964 | -225.222 |
Interest Income (Expense), Net Non-Operating | 17.93 | 8.204 | 25.051 | -4.258 | -9.19 |
Other, Net | -0.367 | -8.021 | -26.187 | 27.026 | 0.691 |
Net Income Before Taxes | -197.623 | -143.188 | -151.638 | 217.732 | -233.721 |
Net Income After Taxes | -194.775 | -140.956 | -101.603 | 175.312 | -76.493 |
Net Income Before Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Net Income | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Income Available to Common Excl. Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Income Available to Common Incl. Extra. Items | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Diluted Net Income | -194.775 | -140.9 | -101.603 | 175.312 | -76.493 |
Diluted Weighted Average Shares | 134.059 | 133.553 | 133.161 | 134.963 | 132.45 |
Diluted EPS Excluding Extraordinary Items | -1.4529 | -1.05501 | -0.76301 | 1.29896 | -0.57752 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.4529 | -1.05501 | -0.76301 | 1.29896 | -0.57752 |
Minority Interest | 0 | 0.056 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 2519.08 | 1562.82 | 772.365 | 402.995 | 117.783 |
Cash and Short Term Investments | 2402.04 | 708.145 | 736.861 | 383.436 | 98.443 |
Cash & Equivalents | 848.631 | 347.815 | 436.575 | 109.335 | 47.598 |
Short Term Investments | 1553.41 | 360.33 | 300.286 | 274.101 | 50.845 |
Prepaid Expenses | 104.356 | 73.003 | 27.511 | 13.378 | 8.579 |
Other Current Assets, Total | 12.681 | 8.594 | 7.993 | 6.181 | 10.761 |
Total Assets | 2802.09 | 1954.27 | 918.761 | 512.071 | 191.596 |
Property/Plant/Equipment, Total - Net | 188.166 | 130.054 | 79.893 | 16.308 | 12.29 |
Property/Plant/Equipment, Total - Gross | 208.909 | 144.546 | 89.125 | 21.14 | 14.006 |
Accumulated Depreciation, Total | -20.743 | -14.492 | -9.232 | -4.832 | -1.716 |
Goodwill, Net | 16.937 | 16.937 | 16.937 | 16.937 | 16.937 |
Intangibles, Net | 32.755 | 33.287 | 33.82 | 35.694 | 36.917 |
Other Long Term Assets, Total | 21.226 | 9.781 | 15.746 | 15.847 | 7.669 |
Total Current Liabilities | 511.029 | 341.242 | 99.064 | 59.206 | 39.908 |
Accounts Payable | 6.422 | 6.521 | 5.077 | 5.881 | 6.473 |
Accrued Expenses | 489.09 | 141.512 | 76.671 | 26.258 | 14.534 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 15.517 | 193.209 | 17.051 | 26.83 | 18.901 |
Total Liabilities | 724.125 | 522.419 | 201.909 | 88.129 | 61.636 |
Total Long Term Debt | 0 | 0 | 0.7 | 0.9 | 0 |
Deferred Income Tax | 3.253 | 18.439 | 3.253 | 3.305 | 3.305 |
Other Liabilities, Total | 209.843 | 162.738 | 98.892 | 24.718 | 18.423 |
Total Equity | 2077.96 | 1431.85 | 716.852 | 423.942 | 129.96 |
Preferred Stock - Non Redeemable, Net | 0 | 309.137 | |||
Common Stock | 0.013 | 0.013 | 0.013 | 0.011 | 0.004 |
Additional Paid-In Capital | 1709.83 | 1571.54 | 1385.3 | 793.051 | 14.669 |
Retained Earnings (Accumulated Deficit) | 377.237 | -138.6 | -667.184 | -368.519 | -193.836 |
Unrealized Gain (Loss) | -9.122 | -1.099 | -1.278 | -0.601 | -0.014 |
Total Liabilities & Shareholders’ Equity | 2802.09 | 1954.27 | 918.761 | 512.071 | 191.596 |
Total Common Shares Outstanding | 133.237 | 131.161 | 127.417 | 107.649 | 109.397 |
Long Term Investments | 23.927 | 201.388 | 24.29 | ||
Current Port. of LT Debt/Capital Leases | 0.265 | 0.237 | |||
Capital Lease Obligations | 0.7 | 0.9 | |||
Total Receivables, Net | 0 | 773.079 | |||
Accounts Receivable - Trade, Net | 0 | 773.079 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 2358.63 | 2519.08 | 2413.62 | 2288.27 | 2567.55 |
Cash and Short Term Investments | 2250.07 | 2402.04 | 2346.48 | 2195.7 | 1260.07 |
Cash & Equivalents | 824.913 | 848.631 | 963.735 | 1505.18 | 812.355 |
Short Term Investments | 1425.16 | 1553.41 | 1382.75 | 690.52 | 447.719 |
Total Receivables, Net | 0 | 0 | 7 | 1223.16 | |
Accounts Receivable - Trade, Net | 0 | 0 | 7 | 1223.16 | |
Prepaid Expenses | 97.602 | 104.356 | 54.18 | 72.417 | 69.911 |
Other Current Assets, Total | 10.957 | 12.681 | 12.955 | 13.147 | 14.402 |
Total Assets | 2665.94 | 2802.09 | 2695.97 | 2618.99 | 2887.13 |
Property/Plant/Equipment, Total - Net | 185.263 | 188.166 | 184.942 | 172.014 | 153.914 |
Property/Plant/Equipment, Total - Gross | 211.512 | 208.909 | 203.866 | 189.38 | 169.817 |
Accumulated Depreciation, Total | -26.249 | -20.743 | -18.924 | -17.366 | -15.903 |
Goodwill, Net | 16.937 | 16.937 | 16.937 | 16.937 | 16.937 |
Intangibles, Net | 32.622 | 32.755 | 32.888 | 33.021 | 33.154 |
Other Long Term Assets, Total | 23.293 | 21.226 | 13.485 | 11.17 | 12.041 |
Total Current Liabilities | 485.288 | 511.029 | 308.203 | 477.868 | 702.361 |
Accounts Payable | 12.149 | 6.422 | 2.722 | 10.618 | 10.955 |
Accrued Expenses | 455.922 | 489.09 | 282.616 | 354.086 | 577.669 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 17.217 | 15.517 | 22.865 | 113.164 | 113.737 |
Total Liabilities | 695.179 | 724.125 | 546.115 | 666.982 | 886.115 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Deferred Income Tax | 3.253 | 3.253 | 18.439 | 18.439 | 18.439 |
Other Liabilities, Total | 206.594 | 209.843 | 219.473 | 170.675 | 165.315 |
Total Equity | 1970.76 | 2077.96 | 2149.85 | 1952.01 | 2001.01 |
Common Stock | 0.013 | 0.013 | 0.013 | 0.013 | 0.013 |
Additional Paid-In Capital | 1737.63 | 1709.83 | 1682.88 | 1656.02 | 1625.79 |
Retained Earnings (Accumulated Deficit) | 236.337 | 377.237 | 478.84 | 303.528 | 380.021 |
Unrealized Gain (Loss) | -3.219 | -9.122 | -11.88 | -7.553 | -4.805 |
Total Liabilities & Shareholders’ Equity | 2665.94 | 2802.09 | 2695.97 | 2618.99 | 2887.13 |
Total Common Shares Outstanding | 133.931 | 133.237 | 133.027 | 132.638 | 132.353 |
Long Term Investments | 49.187 | 23.927 | 34.102 | 97.585 | 103.535 |
Minority Interest | 0.044 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 515.837 | 528.584 | -298.665 | -174.683 | -115.884 |
Cash From Operating Activities | 1663.25 | -47.589 | -190.941 | -129.632 | -94.096 |
Cash From Operating Activities | 6.251 | 5.278 | 4.4 | 3.294 | 1.618 |
Amortization | 0.532 | 0.533 | 1.042 | 1.223 | 1.138 |
Deferred Taxes | -15.186 | 15.186 | -0.052 | -0.48 | |
Non-Cash Items | 490.452 | 31.224 | 72.812 | 32.33 | 7.018 |
Changes in Working Capital | 665.367 | -628.394 | 29.522 | 8.204 | 12.494 |
Cash From Investing Activities | -1193.46 | -140.814 | -9.862 | -256.158 | -60.441 |
Capital Expenditures | -68.028 | -21.817 | -6.549 | -8.94 | -9.935 |
Other Investing Cash Flow Items, Total | -1125.43 | -118.997 | -3.313 | -247.218 | -50.506 |
Cash From Financing Activities | 34.761 | 100.331 | 529.474 | 449.244 | 24.978 |
Financing Cash Flow Items | -1.197 | 0 | -4.248 | 10.14 | |
Issuance (Retirement) of Stock, Net | 36.218 | 100.59 | 533.972 | 444.872 | 14.838 |
Net Change in Cash | 504.553 | -88.072 | 328.671 | 63.454 | -129.559 |
Issuance (Retirement) of Debt, Net | -0.26 | -0.259 | -0.25 | 4.372 | |
Cash Taxes Paid | 252.03 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -140.956 | 515.837 | 617.44 | 442.128 | 518.621 |
Cash From Operating Activities | -125.782 | 1663.25 | 1628.13 | 1510.22 | 550.089 |
Cash From Operating Activities | 5.505 | 6.251 | 4.431 | 2.882 | 1.419 |
Amortization | 0.133 | 0.532 | 0.399 | 0.266 | 0.133 |
Non-Cash Items | -1.189 | 490.452 | 470.308 | 474.401 | 26.002 |
Changes in Working Capital | 10.725 | 665.367 | 535.549 | 590.548 | 3.914 |
Cash From Investing Activities | 98.079 | -1193.46 | -1040.33 | -377.721 | -105.392 |
Capital Expenditures | -6.867 | -68.028 | -55.432 | -36.439 | -15.841 |
Other Investing Cash Flow Items, Total | 104.946 | -1125.43 | -984.894 | -341.282 | -89.551 |
Cash From Financing Activities | 2.344 | 34.761 | 32.75 | 30.765 | 27.685 |
Issuance (Retirement) of Stock, Net | 2.31 | 36.218 | 34.13 | 32.086 | 28.946 |
Issuance (Retirement) of Debt, Net | -0.066 | -0.26 | -0.183 | -0.124 | -0.064 |
Net Change in Cash | -25.359 | 504.553 | 620.551 | 1163.27 | 472.382 |
Financing Cash Flow Items | 0.1 | -1.197 | -1.197 | -1.197 | -1.197 |
Deferred Taxes | -15.186 | ||||
Cash Taxes Paid | 252.03 | 191.653 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
SB Investment Advisers (UK) Limited | Investment Advisor | 12.4275 | 16684041 | -494544 | 2023-06-30 | LOW |
ARCH Venture Partners | Venture Capital | 9.6213 | 12916663 | 3377479 | 2022-09-09 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 9.3355 | 12533053 | 204415 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.6164 | 10225068 | -28854 | 2023-06-30 | LOW |
GSK plc | Corporation | 6.3694 | 8550954 | 0 | 2023-04-03 | LOW |
Scangos (George A) | Individual Investor | 4.2902 | 5759638 | 194250 | 2023-04-03 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.0363 | 5418804 | 34641 | 2023-06-30 | LOW |
Temasek Holdings Pte. Ltd. | Sovereign Wealth Fund | 3.8239 | 5133610 | -681362 | 2023-06-30 | LOW |
Baillie Gifford & Co. | Investment Advisor | 2.9672 | 3983445 | -2581 | 2023-06-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 2.0497 | 2751716 | 2871 | 2023-06-30 | LOW |
Perceptive Advisors LLC | Private Equity | 1.4587 | 1958264 | 1816070 | 2023-06-30 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2594 | 1690777 | 165359 | 2023-06-30 | LOW |
Bill & Melinda Gates Foundation | Foundation | 1.1614 | 1559142 | 0 | 2023-06-30 | LOW |
American Century Investment Management, Inc. | Investment Advisor/Hedge Fund | 1.1021 | 1479560 | 116067 | 2023-06-30 | LOW |
Avidity Partners Management LP | Hedge Fund | 1.0614 | 1425000 | -215200 | 2023-06-30 | HIGH |
Sato (Vicki L) | Individual Investor | 0.9798 | 1315351 | -18000 | 2023-06-30 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.8701 | 1168100 | 7600 | 2023-06-30 | HIGH |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 0.7618 | 1022739 | 977639 | 2023-06-30 | LOW |
Paradigm BioCapital Advisors LP | Investment Advisor | 0.7555 | 1014239 | 1014239 | 2023-06-30 | LOW |
Walleye Capital LLC | Hedge Fund | 0.6431 | 863380 | 863380 | 2023-06-30 | HIGH |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Vir Biotechnology Company profile
Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license, and option agreement Visterra, Inc.; license agreement with The Rockefeller University and MedImmune, Inc.; and collaboration with WuXi Biologics and Alnylam Pharmaceuticals, Inc. The company has a research collaboration agreement with the National Institutes of Health, the National Institute of Allergy and Infectious Diseases, and Vaccine Research Center to advance characterization and development of human monoclonal antibodies against coronaviruses. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.Industry: | Biotechnology & Medical Research (NEC) |
499 Illinois St Ste 500
94158-2521
Income Statement
- Annual
- Quarterly
News

How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com